Cogent Biosciences (NASDAQ: COGT) — Perfil da empresa, notícias e dados financeiros
Cogent Biosciences is a biotechnology company developing precision therapies for genetically defined diseases.
Cogent Biosciences
Cogent Biosciences (NASDAQ:COGT) is a biotechnology company focused on developing precision therapies for genetically defined diseases. Their main projects involve creating innovative treatments that can significantly improve the lives of patients with serious conditions by targeting the underlying genetic causes of these diseases. With a passionate commitment to science and patient care, Cogent Biosciences aims to bring forth novel medicines that offer better efficacy and safety profiles. Their objective is to transform the treatment landscape for conditions currently lacking effective therapies, thereby addressing unmet medical needs and enhancing patient outcomes.
Resumo
Operações
Produtos e/ou serviços de Cogent Biosciences
- A precision therapy targeting specific mutations in gastrointestinal stromal tumors (GIST).
- A novel treatment designed for mastocytosis, focusing on mutations that drive the disease.
- Development of therapies for resistant and difficult-to-treat forms of leukemia.
- A comprehensive diagnostic tool to identify specific mutations in cancers for personalized treatment plans.
- Research collaborations aimed at discovering novel oncology targets and developing targeted therapies.
- Participation in global clinical trials to expand the knowledge and application of precision medicine in oncology.
equipe executiva do Cogent Biosciences
- Andrew R. RobbinsPresident, CEO & Director
- John L. GreenCFO & Principal Accounting Officer
- John Edward RobinsonChief Scientific Officer
- Jessica SachsChief Medical Officer
- Cole PinnowChief Commercial Officer
- Brad BarnettChief Technology Officer
- Christi WaarichSenior Director of Investor Relations
- Evan D. KearnsChief Legal Officer & Corporate Secretary
- Abb HaydenSenior Vice President of Sales
- Erin SchellhammerChief People Officer
Principais indicadores financeiros
Resultados divulgados pela Cogent Biosciences, em USD.
- Cap. de mercado
- 5,6 bi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -2.2
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -333,4 mi | -328,9 mi | |
| 0 | -275,9 mi | -255,9 mi | |
| 0 | -208,1 mi | -192,4 mi | |
| 0 | -147,8 mi | -132,6 mi |